 |
Quick Links |
| Information by Disease |
|
|
|
| Cancer News |
|
|
|
| Conference Coverage |
|
|
|
| AZN | $44.82 | -0.37 (-0.82%)
| | NVS | $53.13 | -0.16 (-0.3%)
| | SNY | $37.67 | -0.01 (-0.03%)
| | GSK | $41.53 | 0.06 (0.14%)
|
|
|
Lymphoma
1018 ISS
| Immunotherapy |
Dynavax Technologies |
I (NHL) |
| AD-Ifng (TG1042) |
Adeno IFN gamma |
Transgene |
II |
| Actimmune |
Interferon |
InterMune |
II (NHL) |
| Affinitak |
Antisense therapy |
Eli Lilly |
II (NHL) |
| AP1903 |
Gene therapy |
Ariad Pharmaceuticals |
II |
| AVI-4126 |
Antisense |
AVI Biopharma |
I |
| BCX-1777 |
PNP-inhibitor |
BioCryst Pharmaceuticals |
I/II |
| Bexxar (tositumomab) |
Radioactive monoclonal antibody |
Corixa, GlaxoSmithKline |
Approved and phase III |
| Campath (alemtuzumab) |
MoAb anti CD52 |
Berlex |
II |
| CMC-544 |
Anti CD22 MoAb vaccine |
Wyeth |
I |
| Elsamitrucin |
Antitumor antibiotic |
Spectrum Pharmaceuticals |
II (NHL) |
| Enzastaurin |
PTKI C-B isoenzyme |
Eli Lilly |
II |
| Epratuzumab |
Monoclonal antibody |
Immunomedics, Inc. |
III |
| Favld |
Idiotype vaccine |
Favrille |
II (NHL) |
| Ganite (gallium) |
Semi metalic |
Genta |
II (NHL) |
| Genasense (oblimersen) |
Antisense therapy |
Genta and Aventis |
III |
| Hu-Max-CD4 T-cell lymphoma |
Monoclonal antibody |
Amgen, Genmab |
II |
| Idec-114 |
Anti-CD80 MoAb |
Biogen/Idec |
I |
| Idiotype immunotherapy |
Idiotype vaccine |
Genitope Corp |
III |
| Idiotype KLH lymphoma vaccine |
Vaccine |
NCI |
III |
| Idiotype tumor vaccine |
Preventive vaccine |
Biovest International |
III |
| Immu-106 |
MoAb anti CD20 |
Immunomedics |
I |
| Interleukin 2 |
Cytokine |
Chiron |
III |
| ISS-1018 |
Immunostimulator |
Dynavax Technologies |
I |
| Liquid IL-2 (adelsleukin) |
Cytokine |
Chiron |
I |
| Lympho RAD |
B lymphocyte stimulator |
Human Genome Science |
I |
| Lymphoscan |
Diagnostic |
Immunomedics |
III |
| MDX-060 |
MoAb anti CD30 |
Human Genome Science |
I |
| My Vax |
Vaccine |
Genitope |
II |
| Nipent (pentostatin) |
Antimetabolite |
SuperGen |
Approved and phase II (NHL) |
| Onco TCS (vincristine) |
Microtubule inhibitor |
Inex Pharmaceuticals |
Approved and phase II |
| Ontak (denileukin) |
Fusion protein |
Ligand Pharmaceuticals |
Approved and phase II |
| Pixantrone - CTI |
DNA intercalator |
Novuspharma |
II |
| Pixantrone - Novuspharma and CTI |
Aza-anthrancenedione |
Novuspharma and CTI |
III |
| Proleukin (aldesleukin) |
Interleukin |
Chiron |
II |
| Promune (CpG 7909) |
TLP9 agonist |
Pfizer |
II |
| Rituxan (rituximab) |
CD20 monoclonal antibody |
Idech Pharmaceuticals and Genentech |
II |
| SAHA |
Histone deacetylase inhibitor |
Aton Pharma |
II |
| SDX-105 (bendamustine) |
Nitrosurea |
Salmedix |
II |
| SGN 30 |
Genetically engineered monoclonal antibody |
Seattle Gentics |
II |
| SR 271425 (thioxanthone) |
Cytotoxic |
Sanofi-Aventis |
I |
| T607 |
Tubulin antagonist |
Tularik, Amgen |
II |
| Temazolomide (temodar) |
Alkylating agent |
Schering |
II |
| temsirolimus (CCI-779) |
mTOR inhibitor |
Wyeth Pharmaceuticals |
II |
| Treanda (bendamustin HCL) |
Alkylator |
Cephalon Pharmaceuticals |
II/III |
| Velcade (bortezomib) |
Proteosome inhibitor |
Millennium |
I |
|
|
For more information contact us at clinicaltrials@cancerconsultants.com
 |
 View Drugs in Pipeline By Disease |
 |
|
|
|
 |
|
 |
|
|
Patient Home
Meeting Calendar
